VRTX:NSD-Vertex Pharmaceuticals Incorporated (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 295.92

Change

-3.14 (-1.05)%

Market Cap

USD 76.11B

Volume

1.44M

Average Target Price

USD 281.82 (-4.76%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals, Inc

-0.54 (-0.08%)

USD65.50B 31.28 21.67
SGEN Seattle Genetics, Inc

-0.61 (-0.35%)

USD30.38B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-4.46 (-3.97%)

USD23.85B 10.60 9.11
INCY Incyte Corporation

-0.38 (-0.35%)

USD23.62B 47.64 35.20
BMRN BioMarin Pharmaceutical Inc

+0.75 (+0.59%)

USD23.14B 201.24 120.72
MRNA Moderna, Inc

+0.49 (+0.80%)

USD22.86B N/A N/A
GMAB Genmab A/S

+0.86 (+2.50%)

USD22.35B 60.04 6.37
ALNY Alnylam Pharmaceuticals, Inc

+0.42 (+0.26%)

USD18.21B N/A N/A
BNTX BioNTech SE

-1.78 (-2.57%)

USD15.72B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.51 (+3.82%)

USD15.64B N/A N/A

ETFs Containing VRTX

Symbol Name Weight Mer Price(Change) Market Cap
BTEK:LSE iShares Nasdaq US Biotech.. 7.98 % 0.35 %

-0.07 (-1.42%)

USD0.22B
BTEE:LSE iShares Nasdaq US Biotech.. 7.98 % 0.35 %

-0.09 (-1.40%)

USD0.22B
IBB iShares Nasdaq Biotechnol.. 7.87 % 0.47 %

+0.75 (+0.54%)

USD8.84B
BTEC:LSE iShares Nasdaq US Biotech.. 7.32 % 0.35 %

-0.09 (-1.43%)

USD0.07B
ZBIO ProShares UltraPro Short .. 7.22 % 0.95 %

N/A

USD2.51M
BIS ProShares UltraShort Nasd.. 7.21 % 0.95 %

-0.08 (-1.04%)

USD0.01B
UBIO ProShares UltraPro Nasdaq.. 6.52 % 0.95 %

N/A

USD0.02B
BBH VanEck Vectors Biotech ET.. 5.42 % 0.35 %

+0.80 (+0.48%)

USD0.47B
ACZ:CA Middlefield American Core.. 5.13 % 0.75 %

N/A

USD0.01B
PBE Invesco Dynamic Biotechno.. 5.06 % 0.57 %

+0.75 (+1.25%)

USD0.24B
HWF:CA Middlefield Health & Well.. 4.71 % 0.85 %

-0.06 (-0.49%)

USD0.05B
LS:CA Middlefield Healthcare & .. 4.20 % 0.85 %

-0.08 (-0.73%)

USD0.08B
FFTY Innovator IBD 50 ETF 3.45 % 0.80 %

+0.71 (+2.01%)

USD0.20B
QGRO American Century U.S. Qua.. 3.12 % 0.29 %

+0.74 (+1.47%)

USD0.19B
BIGT:LSE L&G Pharma Breakthrough U.. 3.08 % 0.75 %

-12.00 (-1.22%)

USD0.02B
ETLI:XETRA L&G Pharma Breakthrough U.. 3.08 % 0.75 %

-0.17 (-1.52%)

USD0.02B
ETLI:F L&G Pharma Breakthrough U.. 3.08 % 0.75 %

-0.13 (-1.15%)

USD0.02B
LNGR Global X Longevity Themat.. 2.86 % 0.50 %

+0.13 (+0.53%)

USD0.03B
BBP Virtus LifeSci Biotech Pr.. 2.71 % 0.79 %

+0.25 (+0.51%)

USD0.03B
YXM:CA CI First Asset Morningsta.. 2.55 % 0.60 %

N/A

USD0.03B
YXM-B:CA CI First Asset Morningsta.. 2.55 % 0.60 %

N/A

N/A
PWC Invesco Dynamic Market ET.. 2.53 % 0.59 %

+1.06 (+1.18%)

USD0.12B
FHH:CA FT AlphaDEX U.S. Health C.. 2.30 % 0.70 %

-0.30 (-0.88%)

USD0.02B
FXH First Trust Health Care A.. 2.28 % 0.62 %

+0.58 (+0.63%)

USD1.93B
CACG ClearBridge All Cap Growt.. 2.25 % 0.54 %

+0.37 (+1.00%)

USD0.17B
XBI SPDR S&P Biotech ETF 2.04 % 0.35 %

+1.73 (+1.50%)

USD4.91B
LABD Direxion Daily S&P Biotec.. 1.84 % 1.06 %

-0.16 (-4.98%)

USD0.08B
RPG Invesco S&P 500 Pure Grow.. 1.55 % 0.35 %

+1.39 (+1.05%)

USD2.30B
XMVU:LSE Xtrackers MSCI USA Minimu.. 1.47 % 0.20 %

-0.43 (-1.11%)

USD4.46M
XMS:CA iShares MSCI Min Vol USA .. 1.47 % 0.30 %

+0.11 (+0.42%)

USD0.07B
XMU:CA iShares MSCI Min Vol USA .. 1.47 % 0.30 %

-0.53 (-0.94%)

USD0.44B
VLQ:CA Vanguard Global Liquidity.. 0.72 % 0.40 %

-0.46 (-1.47%)

USD0.01B
VLIQ:XETRA Vanguard Global Liquidity.. 0.61 % 0.00 %

-0.43 (-1.48%)

USD0.01B
VLIQ:LSE Vanguard Global Liquidity.. 0.61 % 0.00 %

-0.39 (-1.50%)

USD0.01B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.11 (-1.88%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.15% 70% C- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.15% 70% C- 83% B
Trailing 12 Months  
Capital Gain 65.82% 75% C 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.82% 75% C 88% B+
Trailing 5 Years  
Capital Gain 144.78% 85% B 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 144.78% 85% B 86% B
Average Annual (5 Year Horizon)  
Capital Gain 24.93% 74% C 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.93% 73% C 74% C
Risk Return Profile  
Volatility (Standard Deviation) 34.23% 59% F 33% F
Risk Adjusted Return 72.83% 86% B 60% D-
Market Capitalization 76.11B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 50.45 17% F 21% F
Price/Book Ratio 11.68 16% F 11% F
Price / Cash Flow Ratio 48.50 2% F 6% F
EV/EBITDA 37.87 10% F 16% F
Management Effectiveness  
Return on Equity 27.02% 98% A+ 93% A
Return on Invested Capital 17.76% 93% A 91% A-
Return on Assets 13.34% 98% A+ 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.04 58% F 55% F
Short Percent 1.62% 78% C+ 66% D
Beta 0.94 79% C+ 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.